A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations - Asahina, H; Yamazaki, K; Kinoshita, I; Sukoh, N; Harada, M; Yokouchi, H; Ishida, T; Ogura, S; Kojima, T; Okamoto, Y; Fujita, Y; Dosaka-Akita, H; Isobe, H; Nishimura, M (Br J Cancer, 2006)